Olema Oncology

Olema Oncology

Biotechnology Research

San Francisco, California 7,400 followers

About us

Olema Oncology is a biopharmaceutical company developing innovative targeted therapies for women’s cancers. Our lead program, palazestrant, a potential best-in-class complete estrogen receptor antagonist (CERAN), is in development to treat estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. It is being evaluated both as a single agent in an ongoing Phase 3 clinical trial, OPERA-01, and in Phase 1/2 combination studies with CDK4/6 inhibitors (palbociclib and ribociclib), a PI3Ka inhibitor (alpelisib), and an mTOR inhibitor (everolimus). We are supported in our mission by experienced and accomplished scientists and board members, leading healthcare investors and some of the most innovative pharma companies. For more information about the company please visit www.olema.com. Note: Olema will not conduct interviews via text message or messaging platforms and will not ask you to download anything as part of your interview. Though we use third party tools to help with advertising our jobs, please be vigilant in checking that the communication is in fact coming from Olema.

Website
http://olema.com
Industry
Biotechnology Research
Company size
51-200 employees
Headquarters
San Francisco, California
Type
Public Company
Founded
2007
Specialties
pharmaceuticals, biotechnology, drug development, oncology, breast cancer, nuclear receptors, and small molecules

Locations

Employees at Olema Oncology

Updates

Similar pages

Browse jobs